Does tirzepatide (Mounjaro) reduce hospitalizations in heart failure patients with obesity?
Tirzepatide cut the risk of cardiovascular death or worsening heart failure by 38% in obese patients with a specific type of heart failure, while significantly improving quality of life and exercise capacity.
Quick Facts
What This Study Found
Tirzepatide reduced the composite of cardiovascular death or worsening heart failure events by 38% (HR 0.62, p=0.026), and produced a 15% body weight reduction along with clinically meaningful improvements in quality-of-life scores and 6-minute walk distance.
Key Numbers
- 731 patients randomized (364 tirzepatide, 367 placebo)
- Median follow-up: 104 weeks
- CV death or worsening HF: 9.9% vs 15.3% (HR 0.62, p=0.026)
- Worsening HF alone: 8.0% vs 14.2% (HR 0.54)
- CV death: 2.2% vs 1.4% (HR 1.58, not significant, very few events)
- KCCQ-CSS improvement: 19.5 vs 12.7 points (difference 6.9, p<0.001)
- GI-related discontinuation: 6.3% vs 1.4%
How They Did This
International, double-blind, placebo-controlled randomized trial (SUMMIT) enrolling 731 patients; 1:1 randomization to tirzepatide (up to 15 mg/week subcutaneously) or placebo; median 104 weeks follow-up; two co-primary endpoints.
Why This Research Matters
HFpEF is the most common form of heart failure and has almost no proven disease-modifying treatments. Tirzepatide is already approved for diabetes and obesity; this trial opens a new therapeutic indication with significant public health impact, given that obesity is the dominant driver of HFpEF.
The Bigger Picture
Following trials of GLP-1 drugs in heart failure with reduced ejection fraction (STEP-HFpEF), SUMMIT establishes tirzepatide as the most powerful pharmacological treatment yet for obesity-driven HFpEF, and suggests the GIP component may add incremental cardiovascular benefit beyond GLP-1 alone.
What This Study Doesn't Tell Us
Enrolled patients were enriched for obesity-related HFpEF; results may not apply to HFpEF with other causes. Event rates were lower than expected, meaning the trial may have been underpowered for cardiovascular mortality alone. Longer-term durability unknown.
Questions This Raises
- ?How does tirzepatide compare head-to-head to semaglutide in HFpEF patients?
- ?Do patients need to continue tirzepatide indefinitely to preserve cardiovascular benefits?
- ?Is the benefit driven primarily by weight loss or by direct cardiac effects of the drug?
Trust & Context
- Key Stat:
- 38% Reduction in risk of cardiovascular death or worsening heart failure events with tirzepatide vs placebo (HR 0.62, p=0.026)
- Evidence Grade:
- Rated strong: large international double-blind RCT with propensity-matched comparison, dual primary endpoints, and median 2-year follow-up published in NEJM.
- Study Age:
- Published in 2025 in the New England Journal of Medicine; SUMMIT trial ran across multiple countries.
- Original Title:
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Published In:
- The New England journal of medicine, 392(5), 427-437 (2025)
- Authors:
- Packer, Milton(6), Zile, Michael R(6), Kramer, Christopher M(5), Baum, Seth J, Litwin, Sheldon E, Menon, Venu, Ge, Junbo, Weerakkody, Govinda J, Ou, Yang, Bunck, Mathijs C, Hurt, Karla C, Murakami, Masahiro, Borlaug, Barry A
- Database ID:
- RPEP-12912
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
What is heart failure with preserved ejection fraction (HFpEF)?
It is a form of heart failure where the heart pumps normally but is too stiff to fill properly between beats, causing breathlessness, fatigue, and fluid retention. Obesity is its leading driver.
Is tirzepatide approved for heart failure?
As of the trial publication in 2025, tirzepatide was approved for diabetes and obesity—not yet specifically for heart failure. This trial provides the evidence base for a potential expanded indication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12912APA
Packer, Milton; Zile, Michael R; Kramer, Christopher M; Baum, Seth J; Litwin, Sheldon E; Menon, Venu; Ge, Junbo; Weerakkody, Govinda J; Ou, Yang; Bunck, Mathijs C; Hurt, Karla C; Murakami, Masahiro; Borlaug, Barry A. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.. The New England journal of medicine, 392(5), 427-437. https://doi.org/10.1056/NEJMoa2410027
MLA
Packer, Milton, et al. "Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.." The New England journal of medicine, 2025. https://doi.org/10.1056/NEJMoa2410027
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide for Heart Failure with Preserved Ejection Fracti..." RPEP-12912. Retrieved from https://rethinkpeptides.com/research/packer-2025-tirzepatide-for-heart-failure
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.